Qiagen, LLC

Qiagen, LLC, a foreign-owned manufacturer of molecular diagnostics, scientific equipment, and bioinformatics solutions headquartered in Germantown, Maryland, operates as a prime contractor across a sprawling federal portfolio spanning health, defense, law enforcement, and research agencies, competing without set-aside restrictions in the open federal marketplace. The company is a wholly owned subsidiary of Qiagen N.V., a Dutch-registered parent entity.

Qiagen's federal footprint centers on consumable diagnostics, laboratory instrumentation, and bioinformatics software. Core product categories include DNA and RNA extraction kits (EZ1, EZ2, QIAsymphony, QIAcube systems), next-generation sequencing supplies, tuberculosis testing reagents (QuantiFERON TB Gold Plus), digital PCR systems, sample preparation instruments, and specialized genomic analysis software platforms (Ingenuity Pathway Analysis, CLC Genomics Workbench, QIAGEN Clinical Insight). Recent awards exemplify this portfolio: a $2.78 million BPA call from Veterans Integrated Service Network 22 (December 2024) for tuberculosis testing reagents; a $945,938 sole-source definitive contract from the National Cancer Institute (September 2024) for evidence-based bioinformatic interpretation of next-generation sequencing data supporting precision cancer diagnostics; a $317,425 master service agreement with the FBI (June 2025) for preventative maintenance of QIAGEN instruments supporting next-generation sequencing validation; and a $1.78 billion definitive contract from the Office of Logistics and Acquisition Operations (June 2024) for bioinformatics analysis tool access extending through June 2029.

Customer concentration tilts heavily toward federal health and defense entities. The top five funding agencies by potential value account for 56% of the combined award portfolio: the CDC Pittsburgh ($59 million across 255 awards), the Defense Health Agency ($42.3 million across 67 awards), the NIH Office of Logistics and Acquisition Operations ($29.8 million across 114 awards), the FBI Headquarters Division ($20.9 million across 75 awards), and the Army Medical Command ($14.3 million across 125 awards). By award count alone, the top tier is led by the NIH Office of the Director (676 awards, $5.4 million), the CDC's Office of Acquisition Services (279 awards, $5.7 million), and the CDC Pittsburgh (255 awards, $59 million). The divergence between these rankings signals that CDC Pittsburgh and Defense Health Agency place fewer but substantially larger orders, while NIH's Office of the Director and Office of Acquisition Services drive volume through numerous smaller task orders.

Qiagen holds multiple significant indefinite delivery vehicles anchoring its federal business model. A $2.5 million single-award indefinite delivery contract with the FBI Headquarters Division (through April 2030) supplies consumables and reagents for law enforcement operations; a $6.5 million single-award BPA with the Defense Health Agency (through March 2025) procures pharmaceutical products and consumables; a $489,895 single-award IDC with the Defense Health Agency (through September 2030) covers QuantiFERON TB Gold-Plus assays for military medical readiness; a $5.12 million single-award BPA with Veterans Integrated Service Network 22 (through May 2030) supplies tuberculosis testing reagents; a $700,000 single-award IDIQ with Veterans Integrated Service Network 17 (through November 2029) provides QuantiFERON-TB Gold Plus reagents; and a $553,516 single-award BPA with Veterans Integrated Service Network 15 (through October 2030) covers QuantiFERON reagents. The two largest parent vehicles by task-order count are the NIH's HHS BPA HHSN263200100054095B (806 task orders, $4.7 million combined value) and HHS BPA HHSN263201500079B (214 task orders, $2.8 million), reflecting Qiagen's embedded role in the NIH supply chain. Beyond these named vehicles, Qiagen executes task orders against numerous FDA, VA, and interagency IDIQs for molecular biology reagents and diagnostic consumables.

Activity has remained stable across the past five years, averaging 110–122 prime awards annually (2022–2024), with a moderation in 2025 (95 awards) and limited year-to-date data in 2026 (29 awards recorded as of September). The combined potential value across all awards in the portfolio totals $295 million, of which $138.4 million (47%) has been obligated. Within the next twenty-four months, sixty-four awards with combined potential value of $7.8 million face ultimate completion and therefore recompete exposure, indicating a manageable but material recompete pipeline.

NAICS concentration underscores Qiagen's product mix: Analytical Laboratory Instrument Manufacturing dominates (1,664 awards), followed by In-Vitro Diagnostic Substance Manufacturing (319 awards), Other Electronic and Precision Equipment Repair and Maintenance (269 awards), and Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (197 awards). By PSC code, Laboratory Equipment and Supplies (2,933 awards) and Medical and Surgical Instruments, Equipment, and Supplies (827 awards) are the leading categories, with In Vitro Diagnostic Substances, Reagents, Test Kits and Sets (596 awards) and Drugs and Biologicals (473 awards) reflecting the diagnostic and pharmaceutical dimensions of Qiagen's federal business.

Qiagen's subcontractor footprint is minimal: the source identifies only two sub-awards, both under Battelle Memorial Institute (March 2025 and July 2025) for ForenSeq sequencing system service agreements and EZ2 Connect MDx equipment procurement supporting advanced threats research and development for the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense. Additionally, two federal grant sub-awards appear: the Indiana Department of Health (July 2025) for epidemiology and laboratory capacity supporting emerging infectious disease control (CFDA 93.323), and the Delaware Governor's Office (June 2025) for laboratory equipment maintenance (GFR 2025-0581). These sub-award numbers signal that Qiagen operates almost exclusively as a prime contractor to federal agencies rather than as a systemic subcontractor on larger integrator programs.